International Medica Foundation Sublicenses First Rotavirus Vaccine for Newborns in China
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCHESTER, Minn.--(BUSINESS WIRE)--The International Medica Foundation announced today that it has sublicensed to Shanghai BravoBio Co., Ltd. of China, the first rotavirus vaccine that has been clinically tested for use in newborns. This will be the first time that a rotavirus vaccine will be developed for the Chinese market where the first dose of the rotavirus vaccine will be orally administered to newborns. This agreement represents a major milestone in bringing a safer and superior rotavirus vaccine to families in need globally.
Help employers find you! Check out all the jobs and post your resume.
ROCHESTER, Minn.--(BUSINESS WIRE)--The International Medica Foundation announced today that it has sublicensed to Shanghai BravoBio Co., Ltd. of China, the first rotavirus vaccine that has been clinically tested for use in newborns. This will be the first time that a rotavirus vaccine will be developed for the Chinese market where the first dose of the rotavirus vaccine will be orally administered to newborns. This agreement represents a major milestone in bringing a safer and superior rotavirus vaccine to families in need globally.
Help employers find you! Check out all the jobs and post your resume.